Cedra, a division of Worldwide Clinical Trials (WCT), appointed Anthony Busa, Jr., as its new permanent CEO, replacing Cedra founder David Garcia. Thomas Wardle, chief operating officer of WCT, has served as interim CEO since Garcia stepped down earlier this year.
Busa has 34 years of experience within the pharmaceutical and medical devices industries and has held senior management positions at McClintic Busa Group (a clinical trials consulting firm that Busa co-founded in 1998), Dgd Research, Esoterix, Medsites and Covance.
“[Busa] has a thorough understanding of how this business and industry functions,” Wardle said. “He will be a great asset to our team in terms of growth and management.”